This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonnefoy, A. Articles by Girard, A.-M. Search for Related Content PubMed PubMed Citation Articles by Bonnefoy, A. Articles by Girard, A.-M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1688-1692, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1688-1692.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection Models

Alain Bonnefoy,^* Michele Guitton, Carole Delachaume, Pascal Le Priol, and Anne-Marie Girard

Infectious Diseases Group, Microbiology, Aventis Pharma-Hoechst Marion Roussel, 93235 Romainville Cedex, France

Received 14 August 2000/Returned for modification 13 January 2001/Accepted 11 March 2001

We compared the oral antibacterial activities of telithromycin (HMR 3647), a new ketolide drug, in different infections induced in mice by Staphylococcus aureus, Streptococcus pneumoniae, streptococci, enterococci, and Haemophilus influenzae with those of various macrolides and pristinamycin. Unlike all other comparators, telithromycin displayed a high therapeutic activity, particularly in septicemia induced by erythromycin A-resistant pathogens, where the ketolide was the only active compound, displaying effective doses between 3 and 26 mg/kg of body weight. Against H. influenzae, telithromycin was the most effective compound. Telithromycin displayed bacteriostatic behavior against S. pneumoniae and H. influenzae. The ketolide was also active against thigh muscle infection induced by S. aureus. The pharmacokinetic properties of telithromycin accounted for its outstanding well-balanced oral in vivo efficacy against both gram-positive cocci, whatever their phenotype of resistance, and H. influenzae.

---

^* Corresponding author. Mailing address: Infectious Diseases Group, Microbiology, Aventis Pharma-Hoechst Marion Roussel, 102 Route de Noisy, 93235 Romainville Cedex, France. Phone: 33-1-49 91 47 78. Fax: 33-1-49 91 50 61. E-mail: Alain.Bonnefoy{at}aventis.com

---

Antimicrobial Agents and Chemotherapy, June 2001, p. 1688-1692, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1688-1692.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother. 49: 188-194 [Abstract] [Full Text]  
• Tormakangas, L., Alakarppa, H., David, D. B., Leinonen, M., Saikku, P. (2004). Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice. Antimicrob. Agents Chemother. 48: 3655-3661 [Abstract] [Full Text]  
• Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
• Okamoto, H., Miyazaki, S., Tateda, K., Ishii, Y., Yamaguchi, K. (2001). In Vivo Efficacy of Telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother. 45: 3250-3252 [Abstract] [Full Text]